Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
This study showed that patients with LR-MDS treated with luspatercept required significantly less HRU than patients treated with ESA. Further research is warranted to evaluate the financial impact of this lower HRU burden.
Authors
- Manasi Mohan (ORCID: https://orcid.org/0000-0002-1295-5870)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- Samantha Slaff
- Svetlana Gavrilov (ORCID: https://orcid.org/0000-0002-0523-4258)
- Enrico Zanardo (ORCID: https://orcid.org/0009-0009-7011-1180)
- Brian Ball (ORCID: https://orcid.org/0000-0001-8625-7023)
- Ashley Swanson (ORCID: https://orcid.org/0000-0002-3783-1575)
- Mihran Yenikomshian
- Megan Pinaire (ORCID: https://orcid.org/0000-0001-6378-4111)
- Rui Song (ORCID: https://orcid.org/0000-0002-4119-4433)
- Derek Tang
Institutions
- City Of Hope National Medical Center (US)
- Bristol-Myers Squibb (Germany) (DE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1080/13696998.2025.2498852
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00